Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis Optica

Abstract

Tocilizumab might be effective in NMO, here in a patient not responding to leukocyte depletion. Our findings further support data that implicate IL-6 as a critical molecule in the immunopathogenesis of NMO, and a critical role for T cells in the pathogenesis of this disorder.